Surgical outcomes and prognosis of non-small-cell lung cancer in patients with chronic lung diseases: a retrospective analysis

被引:9
|
作者
Choi, Soohwan [1 ]
Park, Jaekil [2 ]
机构
[1] Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, St Vincents Hosp, 93 Jungbudae Ro, Suwon 16247, Gyeonggi Do, South Korea
[2] Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, Seoul St Marys Hosp, Seoul, South Korea
关键词
Lung cancer; Chronic obstructive pulmonary disease; Interstitial lung disease; Combined pulmonary fibrosis and emphysema; COMBINED PULMONARY-FIBROSIS; EMPHYSEMA; SMOKING; TERM; PREVALENCE; RESECTION; SURVIVAL; IMPACT; COPD;
D O I
10.1093/ejcts/ezaa060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: Lung cancer treatment in patients with chronic lung diseases is challenging because postoperative care is difficult and surgical outcomes are poorer than in patients with healthy lungs. This study aimed to examine postsurgical outcomes of patients with comorbid lung diseases treated for lung cancer. METHODS: This retrospective study enrolled 1526 patients who underwent curative surgical resection for non-small-cell lung cancer at a single centre between October 2008 and April 2017. Based on computed tomography findings, patients were assigned to 4 groups and their demographic characteristics, clinicopathological features, surgical outcomes and survival were compared. RESULTS: There were 1101 patients in group A, 266 patients in group B, 62 patients in group C and 97 patients in group D. In the chronic lung disease groups (B, C and D), there was a high percentage of smoking history (86.5%, 79.0% and 92.8%, respectively; P<0.01). The occurrence rate of postoperative lung complications and operative mortality rates were higher in patients with chronic lung disease. Groups A, B, C and D contained 819 (74.4%), 159 (59.8%), 43 (69.4%) and 65 (67.0%) stage I patients, respectively (P<0.01). The groups showed significant differences in overall survival and disease-free survival (all P<0.01). The presence of combined pulmonary fibrosis and emphysema was the only significant negative prognostic factor for overall survival. CONCLUSIONS: The presence of comorbid chronic lung diseases might negatively affect prognosis in patients with non-small-cell lung cancer. The presence of combined pulmonary fibrosis and emphysema could be a negative prognostic factor in lung cancer treatment.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 50 条
  • [21] Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis
    Kuniaki Katsui
    Takeshi Ogata
    Soichi Sugiyama
    Kotaro Yoshio
    Masahiro Kuroda
    Takao Hiraki
    Katsuyuki Kiura
    Yoshinobu Maeda
    Shinichi Toyooka
    Susumu Kanazawa
    Scientific Reports, 11
  • [22] Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis
    Katsui, Kuniaki
    Ogata, Takeshi
    Sugiyama, Soichi
    Yoshio, Kotaro
    Kuroda, Masahiro
    Hiraki, Takao
    Kiura, Katsuyuki
    Maeda, Yoshinobu
    Toyooka, Shinichi
    Kanazawa, Susumu
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] Surgical Outcomes of Pneumonectomy After Induction Therapy for Non-Small-Cell Lung Cancer
    Okumura, N.
    Otsuki, Y.
    Kayawake, H.
    Takahashi, A.
    Nakashima, T.
    Matsuoka, T.
    Yokoyama, T.
    Itasaka, S.
    Yamamoto, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S908 - S909
  • [24] Surgical treatment outcomes on early-stages of non-small-cell lung cancer
    Leila, Fekih
    Mejri, Islam
    Ayari, Aymen
    Smadhi, Hanene
    Kammoun, Hela
    Hassene, Hela
    Greb, Dorra
    Abdelghaffar, Hajer
    Akrout, Ines
    Megdiche, Mohamed Lamine
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [25] Exploration of lung mycobiome in the patients with non-small-cell lung cancer
    Yiming Zhao
    Junqi Yi
    Juanjuan Xiang
    Wei Jia
    Anqi Chen
    Liyu Chen
    Leliang Zheng
    Wen Zhou
    Minghua Wu
    Zheng Yu
    Jingqun Tang
    BMC Microbiology, 23
  • [26] Current surgical treatment of non-small-cell lung cancer
    Van Schil, Paul E.
    Hendriks, Jeroen M.
    Hertoghs, Marjan
    Lauwers, Patrick
    Choong, Cliff
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1577 - 1585
  • [27] Current Surgical Indications for Non-Small-Cell Lung Cancer
    Deboever, Nathaniel
    Mitchell, Kyle G.
    Feldman, Hope A.
    Cascone, Tina
    Sepesi, Boris
    CANCERS, 2022, 14 (05)
  • [28] Exploration of lung mycobiome in the patients with non-small-cell lung cancer
    Zhao, Yiming
    Yi, Junqi
    Xiang, Juanjuan
    Jia, Wei
    Chen, Anqi
    Chen, Liyu
    Zheng, Leliang
    Zhou, Wen
    Wu, Minghua
    Yu, Zheng
    Tang, Jingqun
    BMC MICROBIOLOGY, 2023, 23 (01)
  • [29] Surgical treatment of non-small-cell lung cancer in octogenarians
    Guerra, Miguel
    Neves, Paulo
    Miranda, Jose
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2013, 16 (05) : 673 - 680
  • [30] Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
    Paz-Ares, Luis
    Soulieres, Denis
    Melezinek, Ivan
    Moecks, Joachim
    Keil, Lorenz
    Mok, Tony
    Rosell, Rafael
    Klughammer, Barbara
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (1-2) : 51 - 69